Automate Your Wheel Strategy on ARVN
With Tiblio's Option Bot, you can configure your own wheel strategy including ARVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARVN
- Rev/Share 5.1209
- Book/Share 8.3695
- PB 1.1219
- Debt/Equity 0.0162
- CurrentRatio 5.6369
- ROIC -0.1571
- MktCap 689391217.0
- FreeCF/Share -5.4808
- PFCF -1.7278
- PE -9.4159
- Debt/Assets 0.0109
- DivYield 0
- ROE -0.1201
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ARVN | Goldman | Neutral | Sell | -- | $6 | Oct. 15, 2025 |
| Downgrade | ARVN | BofA Securities | Buy | Neutral | -- | $10 | Sept. 24, 2025 |
| Resumed | ARVN | Barclays | -- | Overweight | -- | $16 | Sept. 17, 2025 |
| Downgrade | ARVN | Leerink Partners | Outperform | Market Perform | -- | $9 | June 2, 2025 |
| Downgrade | ARVN | Truist | Buy | Hold | -- | $11 | May 5, 2025 |
| Downgrade | ARVN | Jefferies | Buy | Hold | -- | $10 | May 2, 2025 |
| Downgrade | ARVN | TD Cowen | Buy | Hold | -- | -- | May 2, 2025 |
| Downgrade | ARVN | Goldman | Buy | Neutral | $70 | $15 | March 13, 2025 |
| Downgrade | ARVN | Wedbush | Outperform | Neutral | $57 | $12 | March 12, 2025 |
| Downgrade | ARVN | Oppenheimer | Outperform | Perform | -- | -- | March 11, 2025 |
News
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Arvinas (ARVN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Arvinas, Inc. (NASDAQ:ARVN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with the afternoon session.
Read More
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.
Read More
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.
Read More
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
Read More
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma –
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 94.9% upside potential for Arvinas (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation
Published: May 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
ARVN ACTIVE INVESTIGATION: Lost Money on Arvinas, Inc.? Contact Levi & Korsinsky Now
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
ATTENTION ARVN SHAREHOLDERS: Investors Who Lost Money on Arvinas, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
An Investigation Has Commenced on Behalf of Arvinas, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARVN Losses.
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
Arvinas, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ARVN
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ARVN.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
ARVN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Arvinas, Inc. Shareholders Who Lost Money
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On May 1, 2025, Arvinas issued a press release announcing a re-prioritization of its vepdegestrant development plan and research portfolio.
Read More
About Arvinas, Inc. (ARVN)
- IPO Date 2018-09-27
- Website https://www.arvinas.com
- Industry Biotechnology
- CEO John G. Houston
- Employees 430